Barclays PLC Has $976,000 Position in ArriVent BioPharma, Inc. (NASDAQ:AVBP)

Barclays PLC raised its stake in ArriVent BioPharma, Inc. (NASDAQ:AVBPFree Report) by 1,124.8% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 41,522 shares of the company’s stock after buying an additional 38,132 shares during the quarter. Barclays PLC owned 0.12% of ArriVent BioPharma worth $976,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Geode Capital Management LLC grew its holdings in shares of ArriVent BioPharma by 154.2% during the 3rd quarter. Geode Capital Management LLC now owns 597,165 shares of the company’s stock valued at $14,036,000 after acquiring an additional 362,221 shares in the last quarter. State Street Corp boosted its position in ArriVent BioPharma by 210.4% during the third quarter. State Street Corp now owns 476,809 shares of the company’s stock valued at $11,205,000 after purchasing an additional 323,186 shares during the last quarter. Suvretta Capital Management LLC grew its stake in ArriVent BioPharma by 7.7% in the third quarter. Suvretta Capital Management LLC now owns 1,845,162 shares of the company’s stock valued at $43,361,000 after purchasing an additional 132,459 shares in the last quarter. MetLife Investment Management LLC increased its position in ArriVent BioPharma by 168.9% in the 3rd quarter. MetLife Investment Management LLC now owns 16,350 shares of the company’s stock worth $384,000 after purchasing an additional 10,269 shares during the last quarter. Finally, BNP Paribas Financial Markets increased its position in ArriVent BioPharma by 32.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 21,965 shares of the company’s stock worth $516,000 after purchasing an additional 5,397 shares during the last quarter. Institutional investors and hedge funds own 9.48% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and issued a $36.00 price target on shares of ArriVent BioPharma in a research note on Friday, November 15th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $36.80.

View Our Latest Analysis on ArriVent BioPharma

ArriVent BioPharma Trading Down 2.2 %

Shares of NASDAQ:AVBP opened at $24.85 on Wednesday. ArriVent BioPharma, Inc. has a 1 year low of $14.35 and a 1 year high of $36.37. The firm has a fifty day moving average price of $28.22 and a 200 day moving average price of $25.69.

ArriVent BioPharma Company Profile

(Free Report)

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.

Recommended Stories

Want to see what other hedge funds are holding AVBP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ArriVent BioPharma, Inc. (NASDAQ:AVBPFree Report).

Institutional Ownership by Quarter for ArriVent BioPharma (NASDAQ:AVBP)

Receive News & Ratings for ArriVent BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArriVent BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.